FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080883443> ?p ?o ?g. }

• W2080883443 endingPage "448" @default.
• W2080883443 startingPage "442" @default.
• W2080883443 abstract "The efficacy of 3 years of annual intravenous administration of zoledronic acid (ZOL) in reducing vertebral and nonvertebral fractures in postmenopausal osteoporosis has been shown by the HORIZON pivotal fracture trial. Histomorphometric analysis of transiliac bone biopsies from the HORIZON participants revealed significantly improved trabecular architecture and reduced bone remodeling for the ZOL-treated versus placebo-treated patients. The aim of our study was to evaluate the cancellous and cortical bone mineralization density distribution (BMDD) in these biopsies by quantitative backscattered electron imaging (qBEI). The study cohort comprised 82 patients on active treatment (ZOL, yearly doses of 5 mg) and 70 treated with placebo, and all received adequate Ca and VitD supplementation. Comparison of ZOL-treated versus placebo-treated cancellous (Cn.) and cortical (Ct.) BMDD-derived variables resulted in significantly higher average (Cn.CaMean + 3.2%, Ct.CaMean + 2.7%) and mode calcium concentrations (Cn.CaPeak + 2.1%, Ct.CaPeak + 1.5%), increased percentages of highly mineralized bone areas (Cn.CaHigh + 64%, Ct.CaHigh + 31%), lower heterogeneity of mineralization (Cn.CaWidth -14%, Ct.CaWidth -13%), and decreased percentages of low mineralized bone areas (Cn.CaLow -22%, Ct.CaLow -26%) versus placebo (all p < 0.001). Cn. BMDD from the patients on active treatment also revealed a statistically significant shift to higher Ca concentrations when compared to a historical normal reference BMDD. These differences in BMDD from ZOL patients compared to the other groups were in line with the correlation of BMDD variables with previously determined cancellous mineralizing surface per bone surface (Cn. MS/BS, a primary histomorphometric index for bone turnover), showing that those with lower Cn. MS/BS had a higher degree of bone matrix mineralization. However, the differences in BMDD variables between the study groups remained when adjusted for Cn. MS/BS, suggesting that other factors in addition to reduced bone turnover might contribute to the higher bone matrix mineralization after ZOL treatment." @default.
• W2080883443 created "2016-06-24" @default.
• W2080883443 creator A5027426647 @default.
• W2080883443 creator A5043303982 @default.
• W2080883443 creator A5052478195 @default.
• W2080883443 creator A5052970674 @default.
• W2080883443 creator A5054657847 @default.
• W2080883443 creator A5067955208 @default.
• W2080883443 creator A5079718233 @default.
• W2080883443 creator A5080846209 @default.
• W2080883443 date "2013-02-15" @default.
• W2080883443 modified "2023-10-10" @default.
• W2080883443 title "Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort" @default.
• W2080883443 cites W1964023148 @default.
• W2080883443 cites W1968200905 @default.
• W2080883443 cites W1989783674 @default.
• W2080883443 cites W1993035292 @default.
• W2080883443 cites W2000177708 @default.
• W2080883443 cites W2000466578 @default.
• W2080883443 cites W2002081436 @default.
• W2080883443 cites W2008147692 @default.
• W2080883443 cites W2009597432 @default.
• W2080883443 cites W2012961078 @default.
• W2080883443 cites W2019582558 @default.
• W2080883443 cites W2023781848 @default.
• W2080883443 cites W2025187567 @default.
• W2080883443 cites W2030615058 @default.
• W2080883443 cites W2047616252 @default.
• W2080883443 cites W2059725989 @default.
• W2080883443 cites W2068523275 @default.
• W2080883443 cites W2071179794 @default.
• W2080883443 cites W2073620907 @default.
• W2080883443 cites W2078761085 @default.
• W2080883443 cites W2080868401 @default.
• W2080883443 cites W2087869843 @default.
• W2080883443 cites W2106406207 @default.
• W2080883443 cites W2120403731 @default.
• W2080883443 cites W2128778774 @default.
• W2080883443 cites W2143254851 @default.
• W2080883443 cites W2149598802 @default.
• W2080883443 cites W2151276667 @default.
• W2080883443 cites W2154465554 @default.
• W2080883443 cites W2170442655 @default.
• W2080883443 doi "https://doi.org/10.1002/jbmr.1780" @default.
• W2080883443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23044788" @default.
• W2080883443 hasPublicationYear "2013" @default.
• W2080883443 type Work @default.
• W2080883443 sameAs 2080883443 @default.
• W2080883443 citedByCount "29" @default.
• W2080883443 countsByYear W20808834432013 @default.
• W2080883443 countsByYear W20808834432014 @default.
• W2080883443 countsByYear W20808834432015 @default.
• W2080883443 countsByYear W20808834432016 @default.
• W2080883443 countsByYear W20808834432017 @default.
• W2080883443 countsByYear W20808834432018 @default.
• W2080883443 countsByYear W20808834432020 @default.
• W2080883443 countsByYear W20808834432022 @default.
• W2080883443 crossrefType "journal-article" @default.
• W2080883443 hasAuthorship W2080883443A5027426647 @default.
• W2080883443 hasAuthorship W2080883443A5043303982 @default.
• W2080883443 hasAuthorship W2080883443A5052478195 @default.
• W2080883443 hasAuthorship W2080883443A5052970674 @default.
• W2080883443 hasAuthorship W2080883443A5054657847 @default.
• W2080883443 hasAuthorship W2080883443A5067955208 @default.
• W2080883443 hasAuthorship W2080883443A5079718233 @default.
• W2080883443 hasAuthorship W2080883443A5080846209 @default.
• W2080883443 hasBestOaLocation W20808834431 @default.
• W2080883443 hasConcept C126322002 @default.
• W2080883443 hasConcept C126894567 @default.
• W2080883443 hasConcept C141071460 @default.
• W2080883443 hasConcept C142724271 @default.
• W2080883443 hasConcept C199343813 @default.
• W2080883443 hasConcept C204787440 @default.
• W2080883443 hasConcept C27081682 @default.
• W2080883443 hasConcept C2776326535 @default.
• W2080883443 hasConcept C2776350087 @default.
• W2080883443 hasConcept C2776541429 @default.
• W2080883443 hasConcept C2781451080 @default.
• W2080883443 hasConcept C2989005 @default.
• W2080883443 hasConcept C71924100 @default.
• W2080883443 hasConcept C72563966 @default.
• W2080883443 hasConceptScore W2080883443C126322002 @default.
• W2080883443 hasConceptScore W2080883443C126894567 @default.
• W2080883443 hasConceptScore W2080883443C141071460 @default.
• W2080883443 hasConceptScore W2080883443C142724271 @default.
• W2080883443 hasConceptScore W2080883443C199343813 @default.
• W2080883443 hasConceptScore W2080883443C204787440 @default.
• W2080883443 hasConceptScore W2080883443C27081682 @default.
• W2080883443 hasConceptScore W2080883443C2776326535 @default.
• W2080883443 hasConceptScore W2080883443C2776350087 @default.
• W2080883443 hasConceptScore W2080883443C2776541429 @default.
• W2080883443 hasConceptScore W2080883443C2781451080 @default.
• W2080883443 hasConceptScore W2080883443C2989005 @default.
• W2080883443 hasConceptScore W2080883443C71924100 @default.
• W2080883443 hasConceptScore W2080883443C72563966 @default.
• W2080883443 hasIssue "3" @default.
• W2080883443 hasLocation W20808834431 @default.
• W2080883443 hasLocation W20808834432 @default.

• next